BLUE : Insider Transactions for Bluebird Bio, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Bluebird Bio, Inc. (BLUE)

$1.02

0.04 (3.77%) as of 4:30 Mon 5/13

Download

Exchange:

N/A

Security Type:

Common

Shares Out:

139,126,000

Market Cap:

141.91(M)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$0.8871 - $4.83

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Biotechnology

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	17,438	35,533	57,514	116,582
Total Sell Value	$26,639	$61,294	$139,194	$443,003
Total People Sold	3	5	5	9
Total Sell Transactions	3	9	12	23
End Date	2024-02-11	2023-11-10	2023-05-12	2022-05-12

Adjust Filter Settings

Records found: 939

Page 18 of 38

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

President and CEO

• • –

2018-01-05

4

S

$173.26

$942,298

D/D

(5,435)

170,297

-

Walsh Jeffrey T.

Chief Financialand Strategy Of

• – –

2018-01-05

4

S

$173.26

$530,530

D/D

(3,060)

24,245

-

Gregory Philip D

Chief Scientific Officer

• – –

2018-01-05

4

S

$173.26

$296,820

D/D

(1,712)

23,772

-

Chief Legal Officer

• – –

2018-01-05

4

S

$173.26

$195,741

D/D

(1,129)

19,798

-

Gregory Philip D

Chief Scientific Officer

• – –

2018-01-03

4

AS

$180.10

$406,550

D/D

(2,250)

25,484

-

Gregory Philip D

Chief Scientific Officer

• – –

2018-01-03

4

OE

$50.51

$63,138

D/D

1,250

27,734

-

Chief Medical Officer

• – –

2018-01-03

4

AS

$179.58

$1,081,781

D/D

(6,000)

15,977

-

Chief Medical Officer

• – –

2018-01-03

4

OE

$5.50

$33,002

D/D

6,000

21,977

-

Wentworth Kory James

Principal Accounting Officer

• – –

2018-01-02

4

A

$0.00

$0

D/D

5,000

5,000

-

President and CEO

• • –

2017-12-13

4

AS

$181.72

$21,629,119

D/D

(117,500)

175,732

-

President and CEO

• • –

2017-12-13

4

OE

$5.50

$208,317

D/D

37,873

293,232

-

Director

– • –

2017-12-11

4

AS

$210.57

$1,516,465

D/D

(7,000)

1,000

-

Director

– • –

2017-12-11

4

OE

$30.47

$182,820

D/D

6,000

8,000

-

Walsh Jeffrey T.

Chief Financialand Strategy Of

• – –

2017-12-11

4

AS

$210.25

$2,143,785

D/D

(9,900)

27,305

-

Walsh Jeffrey T.

Chief Financialand Strategy Of

• – –

2017-12-11

4

OE

$24.47

$242,253

D/D

9,900

37,205

-

Gregory Philip D

Chief Scientific Officer

• – –

2017-12-01

4

AS

$171.81

$388,211

D/D

(2,250)

26,484

-

Gregory Philip D

Chief Scientific Officer

• – –

2017-12-01

4

OE

$50.51

$63,138

D/D

1,250

28,734

-

High Susanna Gatti

Chief Operating Officer

• – –

2017-12-01

4

S

$172.15

$220,696

D/D

(1,282)

13,718

-

Chief Medical Officer

• – –

2017-12-01

4

AS

$171.72

$689,679

D/D

(4,000)

15,977

-

Chief Medical Officer

• – –

2017-12-01

4

OE

$5.50

$22,002

D/D

4,000

19,977

-

Walsh Jeffrey T.

Chief Financialand Strategy Of

• – –

2017-11-10

4

AS

$148.75

$1,480,865

D/D

(9,900)

27,305

-

Walsh Jeffrey T.

Chief Financialand Strategy Of

• – –

2017-11-10

4

OE

$2.09

$197,870

D/D

9,900

37,205

-

President and CEO

• • –

2017-11-01

4

AS

$145.17

$308,779

D/D

(2,127)

255,359

-

President and CEO

• • –

2017-11-01

4

OE

$5.50

$11,699

D/D

2,127

257,486

-

Chief Medical Officer

• – –

2017-11-01

4

AS

$144.44

$580,822

D/D

(4,000)

15,977

-

939 Records found	Previous 10 11 12 13 14 15 16 17 18 19 Next	Page 18 of 38

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.